Cleerly ISCHEMIA vs Eko Murmur Analysis Software (EMAS)

Eko Murmur Analysis Software (EMAS) offers a highly accessible and intuitive mobile application that integrates directly with Eko digital stethoscopes for real-time, point-of-care use. This mobile-first approach provides immediate hands-on usability for a broad range of clinicians. While Cleerly ISCHEMIA provides interactive web-based reports and PowerScribe integration, EMAS's direct interaction with a physical device and mobile app for recording and analysis gives it an edge in immediate user experience.

Cleerly ISCHEMIA provides a more advanced and comprehensive diagnostic assessment of coronary artery disease by deriving functional ischemia, detailed plaque characterization, and prognostic insights from CCTA scans. It has been validated in multiple clinical trials to outperform or be equivalent to other non-invasive measures and has shown prognostic utility for major adverse cardiovascular events (MACE). EMAS, while excellent for early detection and differentiation of heart murmurs, serves more as a screening and decision support tool.

Eko Murmur Analysis Software (EMAS) offers superior pricing transparency and immediate value with a free tier for basic AI analysis, making it highly accessible for initial adoption and evaluation. Its tiered subscription model for full features is clearly outlined. Cleerly ISCHEMIA's pricing is opaque, requiring direct contact for details and varying by provider, which can be a barrier to entry.

Both tools are FDA-cleared, HIPAA compliant, and offer BAAs, demonstrating foundational enterprise readiness. However, Cleerly ISCHEMIA's robust integration capabilities with existing radiology workflows, including API integration with PowerScribe and multiple data transfer methods (VPN, virtual appliance, Nuance Powershare, Intelerad Inteleshare), indicate a more seamless fit into complex imaging department infrastructures. EMAS's mobile-first, cloud-based approach with EHR-compatible PDF reports is strong, but Cleerly's deeper integration into imaging reporting systems provides a slight advantage for large-scale deployments.

Cleerly ISCHEMIA demonstrates a higher degree of innovation by transforming a morphological imaging modality (CCTA) into a tool that provides comprehensive functional and prognostic insights, including non-invasive fractional flow reserve (FFR) estimation and detailed plaque characterization. This represents a significant leap in diagnostic capability for complex coronary artery disease. EMAS, while innovative in democratizing and enhancing auscultation with AI, builds upon an existing clinical practice.

Eko Murmur Analysis Software (EMAS) provides comprehensive support channels, including email, phone, and chat, with specific service level agreements (SLAs) for enterprise customers, indicating a structured and responsive support system. It also offers readily available electronic user manuals and dedicated help centers for both individual and enterprise users. Cleerly provides a general statement about timely support and a contact form but lacks the detailed information on channels, hours, and documentation transparency that EMAS offers.